

All approved abstracts EXCEPT Case Reports and Trials in Progress will be published in the online supplement issue of NEUROENDOCRINOLOGY subsequent to the conference.

All approved abstracts INCLUDING Case Reports and Trials in Progress will be presented in the poster exhibition in the exhibition hall and in MY ENETS after the conference.
(Media Library, www.enets.org/my_enets)

A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS

- (A01)* **Alors-Pérez E et al.** *The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features*
- (A02) **Andreasi V et al.** *Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)*
- (A03) **Balasundaram P et al.** *Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells*
- (A04) **Belz A et al.** *IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung*
- (A05) **Borges de Souza P et al.** *Differential TGF- β Signalling in Typical and Atypical Bronchial Carcinoids*
- (A06) **Capodanno Y et al.** *Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors*
- (A07) **Daskalakis K et al.** *Increased Autophagy/Mitophagy Levels in Pancreatic Neuroendocrine Neoplasms*
- PW (A08) **De Rycke O et al.** *Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton*
- (A09) **Gaspar TB et al.** *Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data*
- (A10) **Grötzinger C et al.** *AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy*
- (A11) **Gurevich L et al.** *Characteristics of the Immunophenotype and the Status of Receptors for Somatostatin Type 2 and 5 of Typical and Atypical Carcinoids of the Lung*
- (A12) **Iyer A et al.** *Functional Consequence of β -Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1*
- (A13) **Kim J et al.** *Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis*
- PW (A14) **Liu D et al.** *Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma*
- (A15) **Liverani C et al.** *DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance*
- (A16) **Mpilla G et al.** *PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors*
- (A17) **Savagner F et al.** *Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors*
- PW (A18) **Shah T et al.** *The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves*
- (A19) **Straub J et al.** *Change of Lactate Transporter (MCT4) Expression in Pancreatic Microadenomas and Stages of Pancreatic Neuroendocrine Tumors*
- (A20) **Terracciano F et al.** *Inhibition of Cyclin Dependent Kinases Overcomes MYC-Driven Secondary Resistance to Everolimus in Digestive NETs*
- (A21) **Teufel A et al.** *Differential Gene Expression May Predict Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)*
- (A22) **Weiβbach J et al.** *Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET*
- OA (A23) **Zuazo-Gaztelu I et al.** *Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents*

B. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS

- PA (B01) **Dayton T et al.** *Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis*
- (B02) **Dijkstra K et al.** *Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma*

- (B03) **Doornebal E et al.** Development of a Personalized Human Immunocompetent Ex-Vivo Model of Neuroendocrine Liver Metastasis Using Precision Cut Tissue Slice Technology
- PW** (B04) **Ear PH et al.** Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
- (B05) **Lauer UM et al.** Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
- (B06) **Mandriani B et al.** Development of Anti-SSTR CAR T Cells for Future Treatment of NETs
- (B07) **Ney A et al.** Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)
- (B08) **Srirajaskanthan R et al.** Development of Ex-Vivo Models of Metastatic Neuroendocrine Neoplasms
- (B09) **Viol F et al.** MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
- (B10) **Wu S et al.** Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models

C. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS

- (C01) **Alcala N et al.** Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
- OA** (C02) **Blazevic A et al.** Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
- (C03) **Blázquez-Encinas R et al.** The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors
- (C04) **Boons G et al.** DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value
- (C05) **Cai W et al.** Mutation Spectrums Analysis of Colorectal Adenocarcinoma and Neuroendocrine Neoplasm Based on Same Genetic Background to Reveal Tumorigenesis
- (C06) **Chen L et al.** Genomic Landscape of Neuroendocrine Neoplasms from Gastrointestinal Tract, Pancreas, Lung, Rare and Unknown Primary Locations
- OA** (C07) **Di Domenico A et al.** Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression
- (C08) **Fernandez-Cuesta L et al.** The PanNENomics Project: A Call for an International Collaborative Effort Built on the Success of the LungNENomics Project
- (C09) **Hackeng WM et al.** Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin
- (C10) **Huang C et al.** Targeted Next Generation Sequencing Analysis Reveals the Genetic Characteristics of Gastric Neuroendocrine Neoplasmas
- PW** (C11) **Klomp I et al.** Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In] In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells
- (C12) **Laddha SV et al.** Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
- (C13) **Refardt J et al.** DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
- PW** (C14) **Riechelmann R et al.** Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors
- OA** (C15) **Sadanandam A et al.** Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours
- PW** (C16) **Samsom K et al.** Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
- (C17) **Schmitz RL et al.** Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms
- PW** (C18) **Sun TY et al.** Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs
- (C19) **Unger N et al.** Molecular Signature of Rectal Neuroendocrine Neoplasia
- OA** (C20) **Venizelos A et al.** Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3
- (C21) **Vicentini C et al.** An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics
- (C22) **Yan S et al.** Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas
- (C23) **Yang KC et al.** Pancreatic Neuroendocrine Neoplasms: Dissecting the Molecular Heterogeneity

D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS

- (D01) **Altieri B et al.** Sporadic Neuroendocrine Neoplasms in Young Adult Patients: Natural History, Prognosis and Management
- (D02) **Amin K et al.** Improving Diagnosis Times as Part of the Transformation of the South Wales NET Service
- (D03) **Apostolidis L et al.** Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
- (D04) **Bambey C et al.** Survival According to Therapy Regimen for siNET: Data from 145 Patients from a German Tertiary Referral Centre, Preliminary Results
- (D05) **Belabdi D et al.** Immunohistochemical Profile of Digestive Neuroendocrine Neoplasms: A Retrospective Analysis in a Single Algerian Institution
- (D06) **Bottiglieri F et al.** Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia
- (D07) **Cai W et al.** Rectal NETs and Rectosigmoid Junction NETs May Need to Be Treated Differently
- (D08) **Cameselle-García S et al.** Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
- (D09) **Carrillo D et al.** Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
- (D10) **Chen J et al.** A Single-Center Retrospective Analysis of Thymic Neuroendocrine Tumor
- (D11) **de Cicco F et al.** Clinical Presentation and Prognosis of Patients with Medullary Thyroid Cancer
- (D12) **De Rycke O et al.** O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
- (D13) **Fatima A et al.** Finding the Risk Factors Associated with Neuroendocrine Tumors of Rectum
- (D14) **Fottner C et al.** Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
- PW** (D15) **Garcia Carbonero R et al.** Epidemiology, Pathological and Clinical Features of 4307 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of the Spanish Neuroendocrine Cancer Registry (R-GETNE)
- (D16) **Garcia Carbonero R et al.** WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)
- (D17) **Geboes K et al.** Incidence of Rectal NEN and Adherence to Pathology Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium
- (D18) **Guzman Ruiz YF et al.** Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases
- (D19) **Hallet J et al.** Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
- (D20) **Harhira I et al.** Clinicopathological Characterization of Gastroenteropancreatic Neuroendocrine Tumors in a Single Institute of North Africa: A Retrospective Study of 80 Cases
- (D21) **Harhira I et al.** Gastroenteropancreatic Neuroendocrine Tumours versus Gastroenteropancreatic Neuroendocrine Carcinoma: Presentation in Tunisian Patients
- (D22) **Harhira I et al.** Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in a Single Institute in North Africa over the Last 16 Years
- (D23) **Hautefeuille V et al.** OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics
- (D24) **Hayes AR et al.** Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience
- (D25) **Hermans B et al.** Unique Metastatic Patterns in Neuroendocrine Neoplasms of Different Primary Origin
- (D26) **Hogg A et al.** Data is Power - Registry Experience at an ENETS COE
- (D27) **Holgerson K et al.** The Patient Journey – Experience from Symptoms to Diagnosis among Patients with Small Intestinal Neuroendocrine Tumours (SINET)
- (D28) **Holmager P et al.** Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)
- (D29) **Hu P et al.** Trends of Incidence and Prognosis of Gastric Neuroendocrine Neoplasms - A Study Based on SEER and Our Multicenter Research

- (D30) **Isiangulova A et al.** *The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population*
- (D31) **Jinhu F et al.** *Clinical Epidemiology Study of Rectal Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study*
- (D32) **Koumarianou A et al.** *Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)*
- (D33) **Laffan A et al.** *Survivorship Care Model for Patients with Metastatic Neuroendocrine Tumors*
- (D34) **Levy S et al.** *Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)*
- (D35) **Li Y et al.** *Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors*
- (D36) **Li D et al.** *Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors*
- (D37) **Massironi S et al.** *Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study*
- (D38) **Meti N et al.** *Different Social Media Neuroendocrine Tumor Indexing Strategies Used by Physicians and Advocacy Groups*
- (D39) **Modica R et al.** *Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)*
- OA (D40) **Partelli S et al.** *Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms \leq 2 cm (ASPEN Study)*
- (D41) **Puliafito I et al.** *Epidemiological Characteristics of Neuroendocrine Tumors: A Retrospective Analysis of a Single Centre*
- (D42) **Radhika Y et al.** *Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community*
- (D43) **Refardt J et al.** *Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis*
- (D44) **Ribeiro S et al.** *Incidence of Appendiceal NEN and Adherence to Pathological Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium*
- (D45) **Rossi RE et al.** *Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups*
- (D46) **Saad A et al.** *Causes of Death Following Neuroendocrine Tumors Diagnosis: A United States Population-Based Analysis*
- (D47) **Sadeh A et al.** *Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours*
- (D48) **Sardo E et al.** *Characteristics and Management of Paragangliomas, 10 Years Experience*
- (D49) **Sonbol M et al.** *Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review*
- (D50) **Sorbye H et al.** *Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours*
- (D51) **Twito O et al.** *Hemicolectomy for Neuroendocrine Neoplasms of the Appendix - Is It Really Necessary?*
- (D52) **Twito O et al.** *Temporal Trends in Incidence, Presentation and Work-Up of Neuroendocrine Neoplasms of the Appendix*
- (D53) **Van Genechten D et al.** *Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis*
- (D54) **Vandamme T et al.** *Comparison of Digestive and Non-Digestive Neuroendocrine Neoplasm Patient Characteristics and Survival in an ENETS Center of Excellence*
- (D55) **Venkataraman H et al.** *MEN1 Associated pNETs: A Case Series from Two Centres of Excellence in the United Kingdom*
- PW (D56) **White BE et al.** *Incidence of Neuroendocrine Neoplasms Reported in England 2015-2017*
- (D57) **Whyand T et al.** *Sarcopenia: Don't Judge a Book by It's Cover*
- (D58) **Yan H et al.** *Risk Factors of the Distant Metastasis in Gastric Neuroendocrine Neoplasms: A 10-Year Retrospective Study in China*
- (D59) **Yang H et al.** *Correlation between Immunohistochemical Markers Expression and Lymph Node Metastasis in Gastroenteropancreatic Neuroendocrine Neoplasms: A Nation-Wide 10-Year Retrospective Clinical Epidemiological Study in China*
- (D60) **Zhang Y et al.** *Risk Stratification of Well-Differentiated Rectal Neuroendocrine Tumors*

E. PATHOLOGY - GRADING, STAGING

- (E01) **Barriuso J et al.** Comparison between Tang and WHO 5th Edition Grade Classification for Goblet Cell Adenocarcinomas
- (E02) **Fatima A et al.** Incidence and Outcome of Brain Metastasis in Patients Diagnosed with Neuroendocrine Neoplasm
- (E03) **Hermans B et al.** Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms
- (E04) **Kankava K et al.** Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
- OA (E05) **Kasajima A et al.** Mimics of Neuroendocrine Neoplasms Identified in a Single Consultation Center between 2009 and 2019
- (E06) **Mamodaly M et al.** When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites
- (E07) **Moonen L et al.** Biopsy Specimen Diagnosis in Pulmonary Carcinoids, A Shot in the Dark
- (E08) **Nakano K et al.** Analysis of Discordance between Biopsy Grade and Surgical Pathology Grade in Resected PanNEN Patients
- (E09) **Swan N et al.** Succinate Dehydrogenase B (SDHB) Immunohistochemical Expression in Pancreatic Neuroendocrine Tumours and Correlation with Somatostatin Receptor Immunohistochemistry
- (E10) **Taboada RG et al.** G3 Neuroendocrine Tumours and Carcinomas: Clinicopathological Features for Distinct Entities
- (E11) **Tacelli M et al.** Diagnostic Accuracy of Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) in the Evaluation of Pancreatic Neuroendocrine Neoplasms (PNEN) Grading
- (E12) **Vilisova S et al.** Histologic Grading of Neuroendocrine Tumors and Its Relationship of Survival
- (E13) **Wong M et al.** Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
- (E14) **Yu J et al.** The Distance from Pathology to Molecular Imaging: SSTR Expression Comparison in 100 Gastroenteropancreatic Neuroendocrine Neoplasms
- (E15) **Yuan B et al.** Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?
- (E16) **Zhang Y et al.** Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?

F. BIOMARKERS

- (F01) **Belli S et al.** Hormonal Ectopic Secretion Syndromes Associated to Neuroendocrine Neoplasia
- PW (F02) **Bodei L et al.** PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
- (F03) **Briganti V et al.** Added Prognostic Value of Molecular Imaging Biomarkers over Proliferation Index in Typical Lung Carcinoid: An FDG PET and SSTR Imaging Study
- (F04) **Chen R et al.** Rb and p53 Status Determination by Immunohistochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms
- (F05) **Delektorskaya V et al.** Nucleophosmin Expression and Relocation in Pancreatic Neuroendocrine Tumors: Preliminary Data
- (F06) **Duschek S et al.** Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland
- (F07) **Fatima A et al.** Role of Biomarkers in Disease Progression of NET
- (F08) **Gao H et al.** The Distinctive Character of Micro-Vasculature and Immune Cell Infiltration in Cystic Pancreatic Neuroendocrine Tumors
- PW (F09) **Garcia-Alvarez A et al.** Impact of Next-Generation Sequencing Analyses on Treatment Management of Patients with Advanced Neuroendocrine Neoplasms
- (F10) **Hadoux J et al.** The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study
- (F11) **Jingbao K et al.** The Role of Serum Concentration Ratio of Neuron-Specific Enolase in the Evaluation of Therapeutic Effect of Neuroendocrine Tumor
- OA (F12) **Knigge U et al.** Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours

- (F13) **Malczewska A et al.** *Diagnosis and Assessment of Effectiveness of Surgical Resection of Small Bowel Neuroendocrine Tumours: The Roles of Circulating MicroRNAs*
- (F14) **Malczewska A et al.** *Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience*
- (F15) **Modlin I et al.** *The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer*
- (F16) **Munoz-Medel M et al.** *Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study*
- PW** (F17) **Öberg K et al.** *A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood*
- (F18) **Ottaiano A et al.** *IMMUNeOCT: OCT LAR in the Induction of Immunologic Response in Patients with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study (EudraCT2017-001613-83)*
- (F19) **Puliani G et al.** *Angiogenetic Markers as Prognostic Predictors in Neuroendocrine Neoplasms*
- (F20) **Ruiz G et al.** *Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status*
- (F21) **Salvatici M et al.** *Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer*
- (F22) **Shah T et al.** *Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results*
- (F23) **Shah H et al.** *Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels*
- (F24) **Syguła A et al.** *Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours*
- (F25) **van Treijen M et al.** *The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent 'Real-World' Validation Study*
- PW** (F26) **Viudez A et al.** *SILVELLUL Project: Development of a New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus*
- (F27) **Zhang W et al.** *Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection*
- (F28) **Zhu X et al.** *Correlation between Clinicopathological Features and Distant Metastases in Pancreatic Neuroendocrine Neoplasm: A National Multicenter 10-Year Retrospective Study*

G. IMAGING AND INTERVENTIONS (RADIOLOGY, ENDOSCOPY)

- (G01) **Blazevic A et al.** *Prediction of Symptomatic Mesenteric Mass in Patients with Small Intestinal Neuroendocrine Tumors Using a CT Radiomics Approach*
- (G02) **Chen X et al.** *Outcome of NET Liver Metastases Treated by TAE Using Microspheres*
- (G03) **de Mestier L et al.** *Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1*
- (G04) **Fatima A et al.** *Cystic Pancreatic Neuroendocrine Tumors. Can We Diagnose Them Preoperatively?*
- (G05) **Feldhaus F et al.** *Palliative CT Brachytherapy in Hepatic Metastatic NET*
- (G06) **Giannone F et al.** *Diagnostic Accuracy of 68Gallium Positron Emission Tomography (68Ga PET), Endoscopic Ultrasound (EUS) and Computed Tomography in the Assessment of Lymphnode Metastases by Nonfunctioning Pancreatic Neuroendocrine Neoplasms*
- (G07) **Jimenez-Fonseca P et al.** *CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study*
- (G08) **Lang M et al.** *Ultrasonography Detects Most pNET*
- (G09) **Massironi S et al.** *Risk of Pre-Operative Understaging of Duodenal Neuroendocrine Tumors at Conventional Imaging: When Surgery Becomes the First Choice*
- (G10) **Monahan H et al.** *Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT*

- (G11) **Peiró I et al.** *68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors*
- (G12) **Puranik A et al.** *Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)*
- (G13) **Smiroldo V et al.** *Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience*
- (G14) **Staal F et al.** *CT-Based Radiomics for Prediction of Outcome after Somatostatin Analogues in Patients with Liver Metastases of a Neuroendocrine Tumor: An Exploratory Study*
- (G15) **Tannoury J et al.** *Interest of PET-MRI in the Management of GIT NETs*
- (G16) **van Beek DJ et al.** *Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort*
- (G17) **Zhang Y et al.** *Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib*

H. MEDICAL TREATMENT - CHEMOTHERAPY SOMATOSTATIN ANALOGUES, INTERFERON

- PA (H01)** **Al-Toubah T et al.** *Somatostatin Analogs (SSA) in Patients with Symptomatic Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)*
- (H02) **Ameziane N et al.** *Somatostatin Analogs in Real World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)*
- (H03) **Bardasi C et al.** *Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience*
- (H04) **Barriuso J et al.** *Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies*
- (H05) **Bengueddach A et al.** *Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm*
- (H06) **Cadiot G et al.** *EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI)*
- (H07) **Carmona-Bayonas A et al.** *Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study*
- (H08) **Couronne T et al.** *Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)*
- (H09) **De Felice I et al.** *Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue*
- (H10) **de Mestier L et al.** *Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers*
- (H11) **De Rycke O et al.** *Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)*
- (H12) **Fagnani F et al.** *Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study*
- (H13) **Feuilly M et al.** *Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review*
- (H14) **Feuilly M et al.** *Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis*
- (H15) **Gertner J et al.** *Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients' Experience*
- (H16) **Hernando J et al.** *Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme*
- (H17) **Ito T et al.** *The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan*
- (H18) **Lacombe C et al.** *Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?*
- (H19) **Massironi S et al.** *Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study*

- (H20) **Merola E et al.** Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is $\geq 10\%$?
- (H21) **Metz DC et al.** Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
- (H22) **Mollazadegan K et al.** Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors
- (H23) **Patel K et al.** The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours
- (H24) **Qi Z et al.** Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues
- (H25) **Ruszniewski P et al.** Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE
- (H26) **Schenk J et al.** Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
- (H27) **Schinzari G et al.** Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
- (H28) **Shi X et al.** Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China
- (H29) **Truong Thanh XM et al.** Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO)
- (H30) **Walter T et al.** Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)

I. MEDICAL TREATMENT - TARGETED THERAPIES

- (I01) **Bongiovanni A et al.** Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis
- (I02) **Dasari A et al.** Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)
- (I03) **Fatima A et al.** Diagnosis and Management of Insulinomas. The Use of Current Practices in Pakistan
- (I04) **Hota S et al.** A Real-World Study of Patients with Carcinoid Syndrome at King's College Hospital on Long-Term Telotristat Therapy
- (I05) **Isiangulova A et al.** Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
- (I06) **Li J et al.** Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
- (I07) **Markovich A et al.** Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
- (I08) **Rinzivillo M et al.** Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
- (I09) **Rodriguez-Freixinos V et al.** Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)
- (I10) **Rowland S et al.** Transcatheter Arterial Embolization (TAE) of NEN Metastases: Efficacy and Predictors of Response
- (I11) **Vandamme T et al.** Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence

J. MEDICAL TREATMENT - OTHERS, NOT SPECIFIED

- (J01) **Armeni E et al.** Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
- (J02) **Chen YY et al.** A Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Neoplasms
- (J03) **Clement D et al.** The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
- (J04) **Clift A et al.** Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

- (J05) **Fottner C et al.** A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
- (J06) **Gertner J et al.** Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?
- (J07) **Glasberg J et al.** METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors
- (J08) **Hernando J et al.** Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENS) Included in Prospective Clinical Trials (CT)
- (J09) **Hu P et al.** Neuroendocrine Neoplasms Arising in Inflammatory Bowel Disease: Clinical Features of 69 Cases and Literature Review
- (J10) **Hu H et al.** The Clinical Outcome of Non-Curative Resection of Small Rectal Neuroendocrine Tumours
- (J11) **Jimenez-Fonseca P et al.** Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
- (J12) **Laing E et al.** Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study
- (J13) **Levy S et al.** Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey
- (J14) **Linder Ekberg K et al.** Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
- (J15) **Mandal N et al.** Difficulties in Providing Palliative Care in Rural India (West Bengal) – Experience of an NGO
- (J16) **Mandal N et al.** Telephonic Communication in Palliative Care for Better Management of Terminal Cancer Patients in Rural India - A NGO Based Approach
- (J17) **Puliafito I et al.** Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience
- (J18) **Rosenberg M et al.** Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms as a Chronic Disease: Preliminary Results
- (J19) **Spada F et al.** A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study
- (J20) **Stelwagen J et al.** Vitamin Supplementation and a Personalized Diet in Patients with Neuroendocrine Tumors: The DIVIT Study
- (J21) **Taboada RG et al.** Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes
- (J22) **Thiis-Evensen E et al.** Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
- (J23) **Wetz C et al.** Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?
- PW** (J24) **Wyld D et al.** The Economic Impact to Patients with Neuroendocrine Tumours
- (J25) **Zaninotto E et al.** Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
- (J26) **Zhang Y et al.** The Clinicopathological Characteristics of Gastrinoma: A Single-Center Retrospective Study

K. NUCLEAR MEDICINE - IMAGING AND THERAPY (PRRT)

- (K01) **Aberle S et al.** 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
- (K02) **Al-Toubah T et al.** Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/ Peritoneal Disease and Potential Role of Corticosteroids in Treatment
- (K03) **Antwi K et al.** Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
- OA** (K04) **Braat A et al.** 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLS Study)
- (K05) **Carlsen EA et al.** 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms

- (K06) **Carmona-Bayonas A et al.** 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
- (K07) **Duan H et al.** Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
- (K08) **Duan H et al.** Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
- (K09) **Gertner J et al.** Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?
- (K10) **Ghaleb N et al.** Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
- (K11) **Huizing D et al.** A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
- (K12) **Huizing D et al.** Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
- (K13) **Huizing D et al.** Inter- and Inpatient Mean Absorbed Dose Variation and Simplification of Dosimetric Workflow after PRRT
- (K14) **Kamel Hasan O et al.** Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
- (K15) **Kim YI et al.** Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy
- (K16) **Kong G et al.** Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes
- OA (K17) **Lee D et al.** Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors
- (K18) **Liberini V et al.** Robustness of Radiomic Features in 68Ga-DOTATOC PET/CT: A Monocentric Experience for Neuroendocrine Tumors
- (K19) **Loft M et al.** 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast
- (K20) **Mapelli P et al.** Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan
- (K21) **Merkel C et al.** Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
- (K22) **Minczeles NS et al.** Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
- (K23) **Mitjavila Casanovas M et al.** Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study
- (K24) **Pauwels E et al.** Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients
- (K25) **Pavlakakis N et al.** Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs)
- (K26) **Radojewski P et al.** Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
- (K27) **Saghebi J et al.** Brain Metastasis in Patients with Neuroendocrine Neoplasia of Gastroenteropancreatic Origin: A Single Centre Experience
- (K28) **Song H et al.** Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience
- (K29) **Song H et al.** Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
- (K30) **Tham WY et al.** Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours
- PW (K31) **Vyakaranam AR et al.** Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

- (K32) **Wee C et al.** *Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review*
- (K33) **Xie Q et al.** *NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis*
- (K34) **Zacho MD et al.** *Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm*
- OA** (K35) **Zidan L et al.** *Theranostic Implication of Molecular Imaging Phenotype of Well-Differentiated Lung Carcinoid by 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT*

L. SURGICAL TREATMENT AND ABLATIVE THERAPIES

- (L01) **Andreasi V et al.** *Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)*
- (L02) **Athar A et al.** *Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors*
- (L03) **Exarchou K et al.** *Type III Gastric Neuroendocrine Neoplasms: Is Local Excision Sufficient in Selected Cases?*
- (L04) **Grana CM et al.** *A New Possibility in SI-NET Surgery by Using a New β - Probe and 90Y-DOTATOC: A Pilot Study*
- (L05) **Guarneri G et al.** *The Number of Positive Nodes Accurately Predicts Recurrence after Distal Pancreatectomy for Nonfunctioning Neuroendocrine Neoplasms*
- (L06) **Heidsma C et al.** *International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Pancreatic Neuroendocrine Tumors*
- (L07) **Kaemmerer D et al.** *Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?*
- (L08) **Linecker M et al.** *ALPPS for Neuroendocrine Liver Metastases Not Suitable for Conventional Hepatic Resection - Interim Analysis of the International ALPPS Registry*
- (L09) **Mastrangelo L et al.** *New Evidence of Emerging Nodal Metastasis in Staging System after Surgical pNET Resection as Predictive Factor for Recurrence. Result from Monocentric Retrospective Series*
- (L10) **Mastrangelo L et al.** *Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors*
- (L11) **Masui T et al.** *Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis*
- (L12) **Milanetto AC et al.** *A Single Centre Experience of Open Surgery for Pancreatic Insulinomas on 88 Patients*
- (L13) **Milanetto AC et al.** *One-Stage Middle-Preserving Pancreatectomy: Indications and Outcomes*
- (L14) **Milanetto AC et al.** *Pancreatic Neuroendocrine Neoplasms and Gastrointestinal Stromal Tumours: A Single-Institution Experience of a Rare Association and Review of the Literature*
- (L15) **Milanetto AC et al.** *Serotonin-Secreting NeuroEndocrine Neoplasms of the Pancreas: Which Are the Primary Pancreatic Carcinoids?*
- (L16) **Monteleone M et al.** *Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters*
- (L17) **Monteleone M et al.** *Post-Transplant Recurrence of Neuroendocrine Tumors*
- (L18) **Nessi C et al.** *Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery*
- OA** (L19) **Pommegaard HC et al.** *Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients*
- (L20) **Sinclair A et al.** *Effects of Debulking Surgery, Transarterial Embolisation (TAE) and Transarterial Chemoembolisation (TACE) on Quality of Life in Patients with Metastatic Ileal and Pancreatic Neuroendocrine Tumours (NETs)*
- (L21) **Victor A et al.** *Gastric Neuroendocrine Neoplasms: Clinical Management and Outcomes in a Cohort of 54 Patients*
- (L22) **Victor A et al.** *Management and Outcomes of Duodenal Neuroendocrine Tumours*

M. NON DIGESTIVE NETS (BRONCHIAL, THYMIC, OTHERS) - DIAGNOSIS AND THERAPY

- (M01) **Friend E et al.** *Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3*
- (M02) **Hoshen MD et al.** *Outcomes Following Surgical Management of Pulmonary Carcinoids – A Tertiary Center Experience*

- (M03) **Kehili H et al.** Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
- (M04) **La Salvia A et al.** Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors
- (M05) **Tanaka H et al.** Survival Related to Treatment of Patients with Metastatic Neuroendocrine Lung Tumors Treated in a Brazilian Center

N. ENDOCRINE MALIGNANCIES (MTC, PHEOCHROMOCYTOMA) - DIAGNOSIS AND THERAPY

- (N01) **Dioca MD et al.** Retrospective Experience with Pheochromocytoma (PH) and Paraganglioma (PG) in a Single Argentinian Institution
- (N02) **Fountain D et al.** Assessment of Quality of Life in Patients with Neuroendocrine Tumours: Results of a Systematic Literature Review
- (N03) **Konsek-Komorowska S et al.** Evaluation of Overall Survival (OS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)
- (N04) **Rossi M et al.** Intracardiac Paragangliomas (PGLs): A Single-Institution Experience
- (N05) **Victor A et al.** Endoscopic Management and Outcomes of Gastro-Duodenal Neuroendocrine Tumours

O. CASE REPORTS

- (O01) **Aliane H et al.** Large-Cell Neuroendocrine Carcinoma of the Lung in Elderly Patient: Case Report and Review of Literature
- (O02) **Aris H et al.** Endometrial Small Cell Neuroendocrine Carcinoma: Case Report and Literature Review
- (O03) **Aris H et al.** Gastroenteropancreatic Neuroendocrine Tumor: Experience of an Algerian Centre
- (O04) **Athar A et al.** Misdiagnosis of Pancreatic Neuroendocrine Carcinoma - A Potential Threat
- (O05) **Babli S et al.** Is It That Rare?
- (O06) **Bai JA et al.** Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1
- (O07) **Bai JA et al.** Patient-Derived Tumor Xenograft Combined with Chemotherapy Drug Sensitivity Test in a Patient with Pancreatic Neuroendocrine Carcinoma
- (O08) **Bengueddach A et al.** Surgical Management of Neuroendocrine Tumor-Associated Liver Metastases
- (O09) **Cruz MA et al.** Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Report and Review of Literature
- (O10) **Cruz MA et al.** Mixed Large and Small Cell Neuroendocrine Carcinoma of the Endometrium: A Case Report and Literature Review
- (O11) **Da Silva Dias D et al.** An Atypical Presentation of a Neuroendocrine Carcinoma of Unknown Origin
- (O12) **Espinola Benza MM et al.** Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma
- (O13) **Huertas Gnecco B et al.** Ectopic Neuroendocrine Carcinoma: An Occult Source of ACTH
- (O14) **Ikram B et al.** Primitive Peripheral Neuroectodermal Tumor: Case Report
- (O15) **Kang KW et al.** Accidental Injection of Unlabeled Lu-177 Caused Catastrophic Consequences in Patients with Neuroendocrine Tumor
- (O16) **Kiesewetter B et al.** Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs
- (O17) **La Salvia A et al.** Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
- (O18) **Liberini V et al.** Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
- (O19) **Lima Ferreira J et al.** Medullary Thyroid Carcinoma and DIPNECH: An Unexpected Association
- (O20) **Lombardi PM et al.** Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report
- (O21) **Markovich A et al.** Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
- (O22) **Martin CS et al.** Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma

- (O23) **Morales Herrero R et al.** Adrenocortical Carcinoma Metastatic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report
- (O24) **Noble J et al.** Prostate Metastasis of Medullary Thyroid Carcinoma in a Young Patient with MEN2B Syndrome
- (O25) **Parlagreco E et al.** Glucagonoma: Still a Misleading Disease and the Importance of Multidisciplinary Neuroendocrine Tumor Board
- (O26) **Qi Z et al.** Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
- (O27) **Rossi RE et al.** Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
- (O28) **Saidi MA et al.** Lymph Node Merkel Cell Carcinoma without Primary: Long Term Survival
- (O29) **Saidi MA et al.** Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review
- (O30) **Saidi MA et al.** Primary Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review
- (O31) **Saunders E et al.** Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab
- (O32) **Scalorbi F et al.** Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
- (O33) **Schmid G et al.** An Infectious Diseases Specialist NET Patient Looks at Management of NETs
- (O34) **Shi Y et al.** Case Report: Whole Exon Sequencing of Primary Lesion and Metastatic Liver Lesion in Pancreatic Neuroendocrine Tumor
- (O35) **Wadsley J et al.** Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden
- (O36) **Wang C et al.** Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor
- (O37) **Zhang Y et al.** Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report
- (O38) **Zhang Y et al.** Treatment of the Pinealoma: Experience from a Rare Case

P. TRIALS IN PROGRESS/TRIALS IN CONCEPT

- (P01) **Galler M et al.** Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors
- (P02) **Hadoux J et al.** FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling
- (P03) **Leyden S et al.** Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients
- (P04) **McNamara M et al.** NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)
- (P05) **Riechelmann R et al.** HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
- (P06) **Santos M et al.** Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
- (P07) **Suh M et al.** First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
- (P08) **Tal I et al.** The Major Role of Neuroendocrine Tumor (NET)-Specialist Nurse in Improving NET Patients Disease-related QoL - Preliminary Data
- (P09) **Teulé A et al.** Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
- (P10) **Trifanov V et al.** Next Generation Sequencing of Pancreatic Neuroendocrine Tumors in Russian Cohort
- (P11) **Walter T et al.** Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
- (P12) **Łowczak A et al.** Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV